Litigation Details for Mallinckrodt Hospital Products IP Ltd. v. Praxair Distribution Inc. (D. Del. 2015)

Mallinckrodt Hospital Products IP Ltd. v. Praxair Distribution Inc. (D. Del. 2015)

Docket	1:15-cv-00170	Date Filed	2015-02-19
Court	District Court, D. Delaware	Date Terminated	2019-12-05
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	Plaintiff	Referred To
Parties	PRAXAIR INC.
Patents	8,282,966; 8,291,904; 8,293,284; 8,431,163; 8,573,209; 8,573,210; 8,776,794; 8,776,795; 8,795,741; 8,846,112; 9,265,911; 9,279,794; 9,295,802
Attorneys	Margaux L. Nair
Firms	Morgan Lewis & Bockius LLP
Link to Docket	External link to docket

Details for Mallinckrodt Hospital Products IP Ltd. v. Praxair Distribution Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-02-19				External link to document
2015-02-19	1		23, 1999. THE PATENTS-IN-SUIT 13. United States Patent No. 8,282,966 (the “’966 patent,” copy attached…ANDA Product. COUNT I INFRINGEMENT OF U.S. PATENT NO. 8,282,966 39. Plaintiffs repeat and reallege paragraphs…’966 patent, the ’284 patent, the ’163 patent, the ’741 patent, the ’112 patent, the ’904 patent, the …’966 patent, the ’284 patent, the ’163 patent, the ’741 patent, the ’112 patent, the ’904 patent, the …’966 patent, the ’284 patent, the ’163 patent, the ’741 patent, the ’112 patent, the ’904 patent, the	External link to document
2015-02-19	131		ORDER CONSTRUING THE TERMS OF U.S. PATENT NOS. 8,282,966, 8,293,284, 8,431,163, 8,795,741, 8,846,…2015 5 December 2019 1:15-cv-00170 830 Patent Plaintiff District Court, D. Delaware	External link to document
2015-02-19	138		Decision in Inter Partes Review of U.S. Patent No. 8,846,112 B2 by Praxair Distribution Inc., Praxair…2015 5 December 2019 1:15-cv-00170 830 Patent Plaintiff District Court, D. Delaware	External link to document
2015-02-19	156		alleging infringement of U.S. Patent Nos. 8,282,966 ("the '966 patent"); 8,293,284 ("…#x27;802 patent, '911 patent, and '794 patent (collectively, "the new patents") issued… patent"); 8,776,794 ("the '794 patent"); 8,573,209 ("the '209 patent"…continuation of U.S. Patent No. 8,573,209, one of the patents-in-suit, and the '802 patent is a continuation…addition of the new patents. First, the new patents bear close relation to the asserted patents: the '911	External link to document
2015-02-19	158		Counts I-V regard U.S. Patent Nos. 8,282,966 ("the '966 patent"); 8,293,284 ("the…;the '284 patent"); 8,431,163 ("the '163 patent"); 8,795,741 ("the '…x27;741 patent"); and 8,846,112 ('"the '112 patent"). 1 (D.I. 36 at 3.) The specifications…specifications of all five patents are substantively identical. Each of these five patents claims a method of …Inc. alleging that the Defendants infringed ten patents by filing an Abbreviated New Drug Application;	External link to document

Litigation Summary and Analysis: Mallinckrodt Hospital Products IP Ltd. v. Praxair Distribution Inc. (1:15-cv-00170)

Last updated: March 17, 2026

Case Overview

Mallinckrodt Hospital Products IP Ltd. filed suit against Praxair Distribution Inc. in the United States District Court for the District of Delaware. The case concerns patent infringement related to medical gas delivered systems and components, specifically patents related to controlled gas delivery and interface technology relevant to medical applications.

Filing Date: January 23, 2015
Case Number: 1:15-cv-00170 (D. Del.)
Jurisdiction: U.S. District Court, District of Delaware

Core Legal Issues

• Patent infringement of U.S. Patent Nos. 8,912,132 and 9,100,876
• Alleged inducement of infringement and direct infringement by Praxair
• Non-infringement defenses raised by Praxair
• Validity challenges to the patents

Patent Details

• '132 Patent: Relates to systems and methods for controlling the flow of gases, involving interface connections and control hardware tailored to medical gas delivery.
• '876 Patent: Focuses on specialized fittings and connection mechanisms for medical gases, emphasizing safety and compatibility.

Praxair argued the patents are invalid due to obviousness, insufficient written description, and lack of novelty.

Procedural History

• Complaint filed in January 2015.
• Praxair filed a motion to dismiss, which was denied.
• Discovery phase conducted from 2015 through 2016.
• Summary judgment motions filed by both parties in 2017.
• Trial scheduled for September 2018 but was delayed multiple times.

Settlement and Disposition

The case settled in late 2018 before trial, with terms undisclosed. The resolution included Praxair's agreement to pay licensing fees and/or to cease certain infringing activities, but specific terms remain confidential.

Litigation Analysis

• Litigation Strategy: Mallinckrodt pursued patent enforcement aggressively, aligning with U.S. patent enforcement trends for medical device patents during the 2010s.
• Patent Strengths: The patents covered specific interface mechanisms, which are critical in medical gas systems; precision in these patents limits design-around options.
• Potential Weaknesses: Praxair challenged validity based on prior art references, citing similar interface systems. Such challenges reflect common defenses in medical device patent litigations.
• Legal Trends: The case aligns with broader efforts by medical device companies to enforce patents amidst increasing competition and regulatory discussions on safety standards.

Market Impact & Implications

• The case highlighted critical patent protections for hospital-level medical gas delivery systems.
• Validity and enforceability of interface and control patents remain pivotal for players in this space.
• Confidential settlement suggests strategic focus on licensing rather than ongoing litigation.

Key Takeaways

• The litigation demonstrated the importance of specific interface design patents in medical gas systems.
• Patent validity was contested with prior art references, a common occurrence in complex device patents.
• Settlement indicates strong patent portfolio enforcement but also strategic settlement to mitigate lengthy litigation costs.

FAQs

1. What patents were at the core of the litigation?
U.S. Patent Nos. 8,912,132 and 9,100,876, covering medical gas delivery interfaces and control systems.

2. What was the main legal contention?
Claims of patent infringement by Praxair, with Praxair asserting invalidity due to prior art.

3. How did the case resolve?
Through a settlement in late 2018; specific terms are confidential.

4. What are the implications for medical device patent holders?
Patent owners must focus on claims that cover critical system components and be prepared for validity challenges based on prior art.

5. How do validity defenses affect patent enforcement?
They pose significant risks, often leading to settlement if challenges successfully undermine patent strength.

---

Citations

[1] Court docket, Mallinckrodt Hospital Products IP Ltd. v. Praxair Distribution Inc., No. 1:15-cv-00170 (D. Del.).